Figure 5.

Human recombinant AnxA1 attenuates the inflammatory phenotype associated with CFTR inhibition. A: Wild-type animals were treated with 50 μg/kg CFTR₁₇₂ 24 hours and one hour before the i.p. injection of 0.1 mg of zymosan (PBS; 500 μl). Mice were treated i.v. with saline (200 μl), 1 μg hrAnxA1 or 50 μg peptide Ac2-26. B: Wild-type and CFTR^−/− mice received 200 μl i.v. vehicle or hrAnxA1 (1 μg) immediately before the administration of zymosan (1 mg) or vehicle i.p. C: Wild-type and CFTR^−/− mice were treated with 50 μg/kg CFTR₁₇₂ 24 hours and 1 hour before the i.p. injection of 0.1 mg of zymosan (PBS; 500 μl). In all sets of experiments peritoneal lavage fluids were collected four hours later, and recruited neutrophils were stained with an anti-Gr1 Ab for flow cytometry analysis. Data are mean ± SEM of five mice per group. A: *P < 0.05 vs. zymosan/vehicle group; **P < 0.05 vs. zymosan/CFTR₁₇₂ treated group. B: *P < 0.05 vs. zymosan group in wild-type mice; **P < 0.05 vs. zymosan group in CFTR^−/− mice. C: *P < 0.05 vs. zymosan/vehicle group.